ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,475.80
0.05%
Dow Jones
38,737.98
-0.10%
US Dollar vs MXN
18.39452
-0.76%
Brent Oil
84.43
0.63%
Bitcoin
64,964.51
-2.29%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. REGENXBIO Inc (RGNX)

  7. REGENXBIO Inc (RGNX) Noticias

RGNX

REGENXBIO (RGNX)

REGENXBIO Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:RGNX
FechaHoraFuenteTítuloSímboloCompañía
18/06/202406:05PR Newswire (US)REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS IINASDAQ:RGNXREGENXBIO Inc
12/06/202406:05PR Newswire (US)REGENXBIO Announces Leadership TransitionNASDAQ:RGNXREGENXBIO Inc
05/06/202406:05PR Newswire (US)REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:RGNXREGENXBIO Inc
04/06/202415:43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RGNXREGENXBIO Inc
03/06/202415:35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RGNXREGENXBIO Inc
14/05/202415:22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RGNXREGENXBIO Inc
10/05/202406:05PR Newswire (US)REGENXBIO to Participate in Upcoming Investor ConferencesNASDAQ:RGNXREGENXBIO Inc
08/05/202415:16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RGNXREGENXBIO Inc
08/05/202415:05PR Newswire (US)REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational HighlightsNASDAQ:RGNXREGENXBIO Inc
01/05/202406:05PR Newswire (US)REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational HighlightsNASDAQ:RGNXREGENXBIO Inc
24/04/202406:05PR Newswire (US)REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing SummitNASDAQ:RGNXREGENXBIO Inc
28/03/202406:05PR Newswire (US)REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMDNASDAQ:RGNXREGENXBIO Inc
27/03/202415:05PR Newswire (US)REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy DaysNASDAQ:RGNXREGENXBIO Inc
08/03/202405:09Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RGNXREGENXBIO Inc
07/03/202405:03Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:RGNXREGENXBIO Inc
06/03/202422:20PR Newswire (US)REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded WarrantsNASDAQ:RGNXREGENXBIO Inc
06/03/202415:10PR Newswire (US)REGENXBIO Announces Proposed Public Offering of Common StockNASDAQ:RGNXREGENXBIO Inc
05/03/202406:05PR Newswire (US)REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE® TRIALNASDAQ:RGNXREGENXBIO Inc
29/02/202415:57PR Newswire (US)REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® TrialNASDAQ:RGNXREGENXBIO Inc
27/02/202415:54Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RGNXREGENXBIO Inc
27/02/202415:05PR Newswire (US)REGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational HighlightsNASDAQ:RGNXREGENXBIO Inc
21/02/202406:05PR Newswire (US)REGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full Year 2023 Financial Results and Recent Operational HighlightsNASDAQ:RGNXREGENXBIO Inc
07/02/202410:40PR Newswire (US)REGENXBIO Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary EndpointNASDAQ:RGNXREGENXBIO Inc
07/02/202406:05PR Newswire (US)REGENXBIO Announces Completion of Enrollment in Cohort 2 and Additional Positive Interim Data in AFFINITY DUCHENNE® TrialNASDAQ:RGNXREGENXBIO Inc
31/01/202406:05PR Newswire (US)REGENXBIO Announces Presentations at the 20th Annual WORLDSymposium 2024NASDAQ:RGNXREGENXBIO Inc
16/01/202413:47PR Newswire (US)REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal DeliveryNASDAQ:RGNXREGENXBIO Inc
10/01/202406:05PR Newswire (US)REGENXBIO Announces Presentation at the Hawaiian Eye and Retina 2024 MeetingNASDAQ:RGNXREGENXBIO Inc
08/01/202406:05PR Newswire (US)U.S. District Court Issues Decision on REGENXBIO and University of Pennsylvania NAV® Technology Patent Infringement LawsuitNASDAQ:RGNXREGENXBIO Inc
29/11/202306:05PR Newswire (US)REGENXBIO Announces Dose Escalation in AFFINITY DUCHENNE® TrialNASDAQ:RGNXREGENXBIO Inc
08/11/202315:05PR Newswire (US)REGENXBIO Announces Updated Strategic Plans and Third Quarter 2023 Financial ResultsNASDAQ:RGNXREGENXBIO Inc
 Showing the most relevant articles for your search:NASDAQ:RGNX

Su Consulta Reciente

TG
A3K3TX
Carrefour
BIT
F34002
Vontobel Financial Produ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados